Silence Therapeutics (SLN) Non-Current Deffered Revenue: 2019-2025
Historic Non-Current Deffered Revenue for Silence Therapeutics (SLN) over the last 7 years, with Sep 2025 value amounting to $55.3 million.
- Silence Therapeutics' Non-Current Deffered Revenue rose 173.37% to $55.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year increase of 173.37%. This contributed to the annual value of $51.8 million for FY2024, which is 30.95% down from last year.
- As of Q3 2025, Silence Therapeutics' Non-Current Deffered Revenue stood at $55.3 million, which was down 1.88% from $56.3 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Non-Current Deffered Revenue ranged from a high of $97.7 million in Q4 2021 and a low of -$90.0 million during Q1 2022.
- In the last 3 years, Silence Therapeutics' Non-Current Deffered Revenue had a median value of -$71.3 million in 2024 and averaged -$13.9 million.
- In the last 5 years, Silence Therapeutics' Non-Current Deffered Revenue tumbled by 30.95% in 2024 and then surged by 176.67% in 2025.
- Over the past 5 years, Silence Therapeutics' Non-Current Deffered Revenue (MRQ) stood at $97.7 million in 2021, then decreased by 23.81% to $74.5 million in 2022, then rose by 0.72% to $75.0 million in 2023, then plummeted by 30.95% to $51.8 million in 2024, then increased by 6.68% to $55.3 million in 2025.
- Its last three reported values are $55.3 million in Q3 2025, $56.3 million for Q2 2025, and $53.3 million during Q1 2025.